从转移性结直肠癌分泌组的蛋白质组学分析得出的预后六基因表达风险评分

IF 3.4 2区 医学 Q1 PATHOLOGY Journal of Pathology Clinical Research Pub Date : 2022-09-22 DOI:10.1002/cjp2.294
Javier Robles, Laura Pintado-Berninches, Issam Boukich, Beatriz Escudero, Vivian de los Rios, Rubén A Bartolomé, Marta Jaén, Ángela Martín-Regalado, María Jesús Fernandez-Aceñero, Juan Ignacio Imbaud, José Ignacio Casal
{"title":"从转移性结直肠癌分泌组的蛋白质组学分析得出的预后六基因表达风险评分","authors":"Javier Robles,&nbsp;Laura Pintado-Berninches,&nbsp;Issam Boukich,&nbsp;Beatriz Escudero,&nbsp;Vivian de los Rios,&nbsp;Rubén A Bartolomé,&nbsp;Marta Jaén,&nbsp;Ángela Martín-Regalado,&nbsp;María Jesús Fernandez-Aceñero,&nbsp;Juan Ignacio Imbaud,&nbsp;José Ignacio Casal","doi":"10.1002/cjp2.294","DOIUrl":null,"url":null,"abstract":"<p>The necessity to accurately predict recurrence and clinical outcome in early stage colorectal cancer (CRC) is critical to identify those patients who may benefit from adjuvant chemotherapy. Here, we developed and validated a gene-based risk-score algorithm for patient stratification and personalised treatment in early stage disease based on alterations in the secretion of metastasis-related proteins. A quantitative label-free proteomic analysis of the secretome of highly and poorly metastatic CRC cell lines with different genetic backgrounds revealed 153 differentially secreted proteins (fold-change &gt;5). These changes in the secretome were validated at the transcriptomic level. Starting from 119 up-regulated proteins, a six-gene/protein-based prognostic signature composed of IGFBP3, CD109, LTBP1, PSAP, BMP1, and NPC2 was identified after sequential discovery, training, and validation in four different cohorts. This signature was used to develop a risk-score algorithm, named SEC6, for patient stratification. SEC6 risk-score components showed higher expression in the poor prognosis CRC subtypes: consensus molecular subtype 4 (CMS4), CRIS-B, and stem-like. High expression of the signature was also associated with patients showing dMMR, CIMP<sup>+</sup> status, and <i>BRAF</i> mutations. In addition, the SEC6 signature was associated with lower overall survival, progression-free interval, and disease-specific survival in stage II and III patients. SEC6-based risk stratification indicated that 5-FU treatment was beneficial for low-risk patients, whereas only aggressive treatments (FOLFOX and FOLFIRI) provided benefits to high-risk patients in stages II and III. In summary, this novel risk-score demonstrates the value of the secretome compartment as a reliable source for the retrieval of biomarkers with high prognostic and chemotherapy-predictive capacity, providing a potential new tool for tailoring decision-making in patient care.</p>","PeriodicalId":48612,"journal":{"name":"Journal of Pathology Clinical Research","volume":null,"pages":null},"PeriodicalIF":3.4000,"publicationDate":"2022-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9535096/pdf/","citationCount":"1","resultStr":"{\"title\":\"A prognostic six-gene expression risk-score derived from proteomic profiling of the metastatic colorectal cancer secretome\",\"authors\":\"Javier Robles,&nbsp;Laura Pintado-Berninches,&nbsp;Issam Boukich,&nbsp;Beatriz Escudero,&nbsp;Vivian de los Rios,&nbsp;Rubén A Bartolomé,&nbsp;Marta Jaén,&nbsp;Ángela Martín-Regalado,&nbsp;María Jesús Fernandez-Aceñero,&nbsp;Juan Ignacio Imbaud,&nbsp;José Ignacio Casal\",\"doi\":\"10.1002/cjp2.294\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>The necessity to accurately predict recurrence and clinical outcome in early stage colorectal cancer (CRC) is critical to identify those patients who may benefit from adjuvant chemotherapy. Here, we developed and validated a gene-based risk-score algorithm for patient stratification and personalised treatment in early stage disease based on alterations in the secretion of metastasis-related proteins. A quantitative label-free proteomic analysis of the secretome of highly and poorly metastatic CRC cell lines with different genetic backgrounds revealed 153 differentially secreted proteins (fold-change &gt;5). These changes in the secretome were validated at the transcriptomic level. Starting from 119 up-regulated proteins, a six-gene/protein-based prognostic signature composed of IGFBP3, CD109, LTBP1, PSAP, BMP1, and NPC2 was identified after sequential discovery, training, and validation in four different cohorts. This signature was used to develop a risk-score algorithm, named SEC6, for patient stratification. SEC6 risk-score components showed higher expression in the poor prognosis CRC subtypes: consensus molecular subtype 4 (CMS4), CRIS-B, and stem-like. High expression of the signature was also associated with patients showing dMMR, CIMP<sup>+</sup> status, and <i>BRAF</i> mutations. In addition, the SEC6 signature was associated with lower overall survival, progression-free interval, and disease-specific survival in stage II and III patients. SEC6-based risk stratification indicated that 5-FU treatment was beneficial for low-risk patients, whereas only aggressive treatments (FOLFOX and FOLFIRI) provided benefits to high-risk patients in stages II and III. In summary, this novel risk-score demonstrates the value of the secretome compartment as a reliable source for the retrieval of biomarkers with high prognostic and chemotherapy-predictive capacity, providing a potential new tool for tailoring decision-making in patient care.</p>\",\"PeriodicalId\":48612,\"journal\":{\"name\":\"Journal of Pathology Clinical Research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2022-09-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9535096/pdf/\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Pathology Clinical Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/cjp2.294\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PATHOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pathology Clinical Research","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cjp2.294","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PATHOLOGY","Score":null,"Total":0}
引用次数: 1

摘要

准确预测早期结直肠癌(CRC)的复发和临床结果对于确定哪些患者可能受益于辅助化疗至关重要。在这里,我们开发并验证了一种基于基因的风险评分算法,用于基于转移相关蛋白分泌改变的早期疾病患者分层和个性化治疗。对具有不同遗传背景的高转移性和低转移性CRC细胞系的分泌组进行定量无标记蛋白质组学分析,发现153种差异分泌蛋白(fold-change >5)。分泌组的这些变化在转录组水平上得到了验证。从119个上调蛋白开始,经过四个不同队列的顺序发现、训练和验证,确定了一个由IGFBP3、CD109、LTBP1、PSAP、BMP1和NPC2组成的基于6个基因/蛋白的预后特征。该特征被用于开发一种名为SEC6的风险评分算法,用于患者分层。SEC6风险评分成分在预后不良的CRC亚型中表达较高:共识分子亚型4 (CMS4)、crisi - b和stem-like。该特征的高表达也与dMMR、CIMP+状态和BRAF突变的患者相关。此外,SEC6信号与II期和III期患者较低的总生存期、无进展间期和疾病特异性生存期相关。基于sec6的风险分层表明,5-FU治疗对低风险患者有益,而只有积极治疗(FOLFOX和FOLFIRI)对II期和III期的高风险患者有益。总之,这种新颖的风险评分证明了分泌组室作为生物标志物的可靠来源的价值,具有高预后和化疗预测能力,为患者护理的定制决策提供了潜在的新工具。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
A prognostic six-gene expression risk-score derived from proteomic profiling of the metastatic colorectal cancer secretome

The necessity to accurately predict recurrence and clinical outcome in early stage colorectal cancer (CRC) is critical to identify those patients who may benefit from adjuvant chemotherapy. Here, we developed and validated a gene-based risk-score algorithm for patient stratification and personalised treatment in early stage disease based on alterations in the secretion of metastasis-related proteins. A quantitative label-free proteomic analysis of the secretome of highly and poorly metastatic CRC cell lines with different genetic backgrounds revealed 153 differentially secreted proteins (fold-change >5). These changes in the secretome were validated at the transcriptomic level. Starting from 119 up-regulated proteins, a six-gene/protein-based prognostic signature composed of IGFBP3, CD109, LTBP1, PSAP, BMP1, and NPC2 was identified after sequential discovery, training, and validation in four different cohorts. This signature was used to develop a risk-score algorithm, named SEC6, for patient stratification. SEC6 risk-score components showed higher expression in the poor prognosis CRC subtypes: consensus molecular subtype 4 (CMS4), CRIS-B, and stem-like. High expression of the signature was also associated with patients showing dMMR, CIMP+ status, and BRAF mutations. In addition, the SEC6 signature was associated with lower overall survival, progression-free interval, and disease-specific survival in stage II and III patients. SEC6-based risk stratification indicated that 5-FU treatment was beneficial for low-risk patients, whereas only aggressive treatments (FOLFOX and FOLFIRI) provided benefits to high-risk patients in stages II and III. In summary, this novel risk-score demonstrates the value of the secretome compartment as a reliable source for the retrieval of biomarkers with high prognostic and chemotherapy-predictive capacity, providing a potential new tool for tailoring decision-making in patient care.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Pathology Clinical Research
Journal of Pathology Clinical Research Medicine-Pathology and Forensic Medicine
CiteScore
7.40
自引率
2.40%
发文量
47
审稿时长
20 weeks
期刊介绍: The Journal of Pathology: Clinical Research and The Journal of Pathology serve as translational bridges between basic biomedical science and clinical medicine with particular emphasis on, but not restricted to, tissue based studies. The focus of The Journal of Pathology: Clinical Research is the publication of studies that illuminate the clinical relevance of research in the broad area of the study of disease. Appropriately powered and validated studies with novel diagnostic, prognostic and predictive significance, and biomarker discover and validation, will be welcomed. Studies with a predominantly mechanistic basis will be more appropriate for the companion Journal of Pathology.
期刊最新文献
Challenges for pathologists in implementing clinical microbiome diagnostic testing The expression of YAP1 and other transcription factors contributes to lineage plasticity in combined small cell lung carcinoma TROP2 in colorectal carcinoma: associations with histopathology, molecular phenotype, and patient prognosis Predicting lymph node recurrence in cT1-2N0 tongue squamous cell carcinoma: collaboration between artificial intelligence and pathologists VEGFA gene variants are associated with breast cancer progression
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1